OpenAI acquires Orchestra Bio to accelerate drug development with AI agents. The deal merges Orchestra Bio’s expertise into OpenAI’s Rosalind life‑sciences platform, aiming to streamline trial coordination and problem detection for pharma teams. The move follows OpenAI’s collaborations with Novo Nordisk and Moderna on AI‑driven research.
Opening Kapyn…